Catalyst Biosciences Inc (CBIO)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

611 GATEWAY BLVD., SUITE 710 SOUTH SAN FRANCISCO, CA 94080

Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Its protease engineering platform has generated two late-stage clinical programs, including MarzAA, a subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. Its complement pipeline includes a pre-clinical C3-degrader program partnered with Biogen for dry age-related macular degeneration, an improved complement factor I protease for SQ replacement therapy in patients with CFI deficiency and C4b-degraders designed to target disorders of the classical complement pathway as well as other complement programs in development.

Data as of 2021-08-02 07:48:48 -0400
Market Cap127.593 Million Shares Outstanding31.35 Million Avg 30-day Volume238.528 Thousand
P/E Ratio-1.70977 Dividend Yield EPS-3.3
Price/Sales21.09 Debt to Equity1.14 EBITDA-74.582 Million
Price to Book Value1.23 Forward PE24.42 Enterprise Value20.593 Million
Total Cash107 Million Current Debt14.181 Million Gross Profit-115 Thousand
BETA0.8092 52-week High/Low7.55 / 4.03 Next Earnings Date2021-08-05 Price to Cash FLow (P/CF) -6.0454
Data provided by IEX Cloud
View SEC Filings from CBIO instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 2 0.0% 2 (0.12%) 2 (0.12%) 0.0%
Funds Holding: 89 82 8.54% 32 (1.88%) 31 (1.8%) 3.23%
13F shares: 22.355 Million 14.367 Million 55.6% 16.182 Million 8.991 Million 79.99%
% Ownership 71.3517 65.0159 9.75% 51.6499 40.687 26.94%
New Positions: 17 18 -5.56% 6 6 0.0%
Increased Positions 39 31 25.81% 15 10 50.0%
Closed Positions 10 15 -33.33% 5 7 -28.57%
Reduced Positions 18 18 0.0% 8 12 -33.33%
Total Calls 470.846 Thousand 293.745 Thousand 60.29% 45 Thousand 257.8 Thousand -82.54%
Total Puts 69.951 Thousand 12.1 Thousand 478.11% 14.9 Thousand 12.1 Thousand 23.14%
PUT/CALL Ratio 0.15 0.04 275.0% 0.33 0.05 560.0%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding CBIO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CBIO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BLOUSE GRANT E. CHIEF SCIENTIFIC OFFICER

  • Officer
1,754 2021-07-12 1

DESOUZA ERROL B

  • Director
40,213 2021-06-09 4

LAWLOR AUGUSTINE

  • Director
56,949 2021-06-09 4

HUNT ANDREA

  • Director
32,883 2021-06-09 4

WILLIAMS EDDIE

  • Director
33,516 2021-06-09 4

TETLOW SHARON

  • Director
14,000 2021-06-09 1

LING GEOFFREY M.D.

  • Director
30,077 2021-06-09 4

USMAN NASSIM PRESIDENT & CEO

  • Officer
  • Director
286,581 2021-04-05 5

LEVY HOWARD CHIEF MEDICAL OFFICER

  • Officer
23,390 2021-02-09 4

MUSIL CLINTON CHIEF FINANCIAL OFFICER

  • Officer
54,000 2021-02-08 2

RICHARD JOHN P

  • Director
3,716 2020-03-13 0

CAI VERONICA CONTROLLER

  • Officer
7,353 2020-03-13 0

PAYNE FLETCHER CHIEF FINANCIAL OFFICER

  • Officer
No longer subject to file 2019-08-30 0

HILL STEPHEN A

  • Director
1,190 2018-09-06 0

JFL CAPITAL MANAGEMENT, LLC

  • 5% OWNER
0 2018-07-27 0

FLYNN JAMES E

DEERFIELD MGMT L.P.

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

DEERFIELD PARTNERS, L.P.

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
5,661,484 2018-03-06 0

FLYNN JAMES E

DEERFIELD MGMT L.P.

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
1,113,222 2018-03-06 0

SELICK HAROLD E

  • Director
0 2018-01-16 0

MADISON EDWIN CHIEF SCIENTIFIC OFFICER

  • Officer
0 2015-10-22 0

HIMAWAN JEFF

  • Director
0 2015-08-20 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INC/IL

LAMPERT MARK N

BVF INVESTMENTS LLC

INVESTMENT 10 LLC

  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
No longer subject to file 2015-08-20 0

ESSEX WOODLANDS HEALTH VENTURES VIII, L.L.C.

ESSEX WOODLANDS HEALTH VENTURES VIII, L.P.

  • 10% Owner
1,179,352 2015-08-20 0

HODGES MAURI K TREASURER, CFO

  • Officer
No longer subject to file 2015-08-14 0

BLIXT CHARLES A

  • Director
No longer subject to file 2015-08-14 0

DUNTON ALAN W

  • Director
No longer subject to file 2015-08-14 0

BROWN JULIA R

  • Director
No longer subject to file 2015-08-14 0

ROCK PATRICK C. SECRETARY, GC

  • Officer
No longer subject to file 2015-08-14 0

MUSSO ALAN A SVP, FIN+ADMIN, CFO & TREAS

  • Officer
57,799 2014-10-17 0

TOLER STEVEN M. VP, CLIN PHARM SCIENCES

  • Officer
46,000 2014-10-17 0

HOSFORD DAVID A. VP, CLIN DEV & REG AFFAIRS

  • Officer
0 2014-01-23 0

BARRIS PETER J

  • 10% Owner
4,563,512 2013-12-05 0

SANDELL SCOTT D

  • 10% Owner
4,563,512 2013-12-05 0

BARRETT M JAMES

  • 10% Owner
4,563,512 2013-12-03 0

SKALETSKY MARK B

  • Director
0 2013-06-07 0

ZORN PETER A SVP, LGL AFFRS, GC & SECRETARY

  • Officer
0 2013-01-17 0

BRENNAN JEFFREY P SVP, BUS. AND COMM. DEV. & CBO

  • Officer
0 2013-01-17 0

BENCHERIF MEROUANE SVP AND SENIOR SCIEN FELLOW

  • Officer
0 2013-01-17 0

HICKS KAREN A VP, HUMAN RESOURCES

  • Officer
0 2013-01-17 0

INVESTMENT 10 LLC

  • SEE EXPLANATION OF RESPONSES
6,171,669 2013-01-01 0

KRAMLICH C RICHARD

  • 10% Owner
4,568,845 2012-11-19 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INC/IL

LAMPERT MARK N

BVF INVESTMENTS LLC

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES SEE EXPLANATION OF RESPONSES
8,616,634 2012-11-14 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
5,710,899 2012-11-07 0

BURRILL STEVEN

  • Director
4,333 2012-07-31 0

SNYDERMAN RALPH

  • Director
0 2012-06-07 0

DEBETHIZY J DONALD PRESIDENT AND CEO

  • Officer
  • Director
0 2012-05-04 0

CALDWELL WILLIAM S SVP - DRUG DISCOVERY AND DEV.

  • Officer
9,235 2011-09-20 0

DUNBAR GEOFFREY C SVP, CLIN. DEV. & REG. AFFAIRS

  • Officer
0 2011-03-29 0

NEWHALL CHARLES W III

  • 10% Owner
4,565,512 2008-01-17 0

PERRY MARK W

  • 10% Owner
4,565,512 2008-01-17 0

TRAINOR III EUGENE A

  • 10% Owner
4,563,512 2008-01-17 0

NEA PARTNERS 10 L P

  • 10% Owner
4,563,512 2008-01-17 0

NEW ENTERPRISE ASSOCIATES 10 L P

  • 10% Owner
4,563,512 2008-01-17 0

JONES ELAINE V

  • FORMER DIRECTOR AS OF 6/13/07
No longer subject to file 2007-11-29 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

DESOUZA ERROL B - Director

2021-07-02 09:51:33 -0400 2021-07-01 A 3,406 a 26,213 direct -1.8433 7.1429 7.1429 6 -4.1475 4

WILLIAMS EDDIE - Director

2021-07-02 09:56:33 -0400 2021-07-01 A 1,414 a 19,516 direct -1.8433 7.1429 7.1429 6 -4.1475 4

LING GEOFFREY M.D. - Director

2021-07-02 09:54:57 -0400 2021-07-01 A 2,713 a 16,077 direct -1.8433 7.1429 7.1429 6 -4.1475 4

LAWLOR AUGUSTINE - Director

2021-07-02 09:54:11 -0400 2021-07-01 A 5,542 a 18,734 direct -1.8433 7.1429 7.1429 6 -4.1475 4

HUNT ANDREA - Director

2021-07-02 09:53:24 -0400 2021-07-01 A 2,886 a 18,883 direct -1.8433 7.1429 7.1429 6 -4.1475 4

LAWLOR AUGUSTINE - Director

2021-07-02 09:54:11 -0400 2021-06-09 A 14,000 a 14,000 direct

TETLOW SHARON - Director

2021-07-02 09:55:42 -0400 2021-06-09 A 14,000 a 14,000 direct

HUNT ANDREA - Director

2021-07-02 09:53:24 -0400 2021-06-09 A 14,000 a 14,000 direct

DESOUZA ERROL B - Director

2021-07-02 09:51:33 -0400 2021-06-09 A 14,000 a 14,000 direct

WILLIAMS EDDIE - Director

2021-07-02 09:56:33 -0400 2021-06-09 A 14,000 a 14,000 direct

LING GEOFFREY M.D. - Director

2021-07-02 09:54:57 -0400 2021-06-09 A 14,000 a 14,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
CATALYST BIOSCIENCES INC CBIO 2021-08-03 13:45:03 UTC -0.4262 0.4862 2100000
CATALYST BIOSCIENCES INC CBIO 2021-08-03 13:15:03 UTC -0.4262 0.4862 2100000
CATALYST BIOSCIENCES INC CBIO 2021-08-03 12:45:03 UTC -0.4262 0.4862 2100000
CATALYST BIOSCIENCES INC CBIO 2021-08-02 22:15:03 UTC -0.4262 0.4862 2100000
CATALYST BIOSCIENCES INC CBIO 2021-08-02 21:45:03 UTC -0.4262 0.4862 2100000
CATALYST BIOSCIENCES INC CBIO 2021-08-02 21:15:03 UTC -0.4262 0.4862 2100000
CATALYST BIOSCIENCES INC CBIO 2021-08-02 20:45:03 UTC -0.4262 0.4862 2100000
CATALYST BIOSCIENCES INC CBIO 2021-08-02 20:15:03 UTC -0.4262 0.4862 2100000
CATALYST BIOSCIENCES INC CBIO 2021-08-02 19:45:03 UTC -0.4262 0.4862 2100000
CATALYST BIOSCIENCES INC CBIO 2021-08-02 19:15:03 UTC -0.4262 0.4862 2100000
CATALYST BIOSCIENCES INC CBIO 2021-08-02 18:45:03 UTC -0.4262 0.4862 2100000
CATALYST BIOSCIENCES INC CBIO 2021-08-02 18:15:03 UTC -0.4262 0.4862 2100000
CATALYST BIOSCIENCES INC CBIO 2021-08-02 17:45:03 UTC -0.4262 0.4862 2100000
CATALYST BIOSCIENCES INC CBIO 2021-08-02 17:15:03 UTC -0.4262 0.4862 2100000
CATALYST BIOSCIENCES INC CBIO 2021-08-02 16:45:03 UTC -0.4062 0.4862 2100000
CATALYST BIOSCIENCES INC CBIO 2021-08-02 16:15:03 UTC -0.4062 0.4862 2100000
CATALYST BIOSCIENCES INC CBIO 2021-08-02 15:45:03 UTC -0.4062 0.4862 2100000
CATALYST BIOSCIENCES INC CBIO 2021-08-02 15:15:03 UTC -0.4062 0.4862 2100000
CATALYST BIOSCIENCES INC CBIO 2021-08-02 14:45:03 UTC -0.3507 0.4307 2100000
CATALYST BIOSCIENCES INC CBIO 2021-08-02 14:15:03 UTC -0.3507 0.4307 2000000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments